Morcellator

Olympus Launches New Gynecologic Power Morcellator for Its Contained Tissue Extraction System

Retrieved on: 
Wednesday, November 30, 2022
Morcellator, Fibroid, Communication, American College of Obstetricians and Gynecologists, Malignancy, American College, Multimedia, Safety, AAGL, Patient, Hysterectomy, Disease, Committee, ACOG, Olympus, FDA, Pharmaceutical industry, Medical device, Birth control, Gynaecology

CENTER VALLEY, Pa., Nov. 30, 2022 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today the market launch of the moresolution™ Power Morcellator, which is manufactured by TROKAMED GmbH  and is available in the U.S. through a distribution agreement with Olympus America, Inc. The moresolution Morcellator is designed for advanced gynecologic procedures with large, calcified tissue specimens.

Key Points: 
  • The moresolution Morcellator is designed for advanced gynecologic procedures with large, calcified tissue specimens.
  • Current FDA Guidance on power morcellator labeling requires that all power morcellators marketed in the U.S. be used with a compatible, FDA-cleared containment device.1 The Olympus Contained Tissue Extraction System comprises the PneumoLiner, a first-of-its-kind containment device, and the moresolution Morcellator, which together provide select patients a laparoscopic surgical option as an alternative to open hysterectomy or open myomectomy for tissue removal.
  • Contained tissue extraction is not indicated for use withwomen who have a known or suspected malignancy.
  • Features and benefits of the moresolution Morcellator include:
    "We are excited to offer a new power morcellation solution for minimally invasive gynecological procedures," said Richard Reynolds, President of the Medical System Group at Olympus America, Inc. "Olympus supports the safe use of power morcellators with a contained extraction system according to FDA guidance.

AROA BIOSURGERY ANNOUNCES HALF YEAR RESULTS

Retrieved on: 
Tuesday, November 29, 2022
COVID-19, Management, Profit and loss sharing, Environment, EBITDA, ARX, ECM, Healing, Multimedia, Australian Securities Exchange, ASX, Extracellular matrix, Patient, USD, Myriad, Matrix, Sheep, Disease, Vacuum, Constant, Distortion, GAAP, Symphony, Morcellator, Pharmaceutical industry, Bank, Online shopping

AUCKLAND, New Zealand, Nov. 29, 2022 /PRNewswire/ -- Today New Zealand based soft-tissue regeneration company Aroa Biosurgery (AROA, the Company) is pleased to announce financial results for H1 FY23.

Key Points: 
  • AUCKLAND, New Zealand, Nov. 29, 2022 /PRNewswire/ -- Today New Zealand based soft-tissue regeneration company Aroa Biosurgery (AROA, the Company) is pleased to announce financial results for H1 FY23.
  • Aroa reports a strong cash balance of NZ$50.1 million as at 30 September 2022 and is debt free.
  • Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'.
  • Founded in 2008, Aroa Biosurgery is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX).

Olympus Launches New Gynecology Contained Extraction System for Manual Tissue Morcellation

Retrieved on: 
Wednesday, September 14, 2022
Laparoscopy, Olympus, Bleeding, Endoscopy, Abdominal cavity, Hematoma, ASC, Superior, Partnership, Infection, Patient, Technology, Quality of life, Abdominal wall, Cell, Peritonitis, Integration, Surgeon, Method, Percussion section, Multimedia, Pneumoperitoneum, View, Medicine, Morcellator, Dentistry, Medical device, Security printing

CENTER VALLEY, Pa., Sept. 14, 2022 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today the market launch of the Guardenia™ Contained Extraction System. Guardenia is the latest innovation in their contained tissue extraction product portfolio for gynecological procedures and is manufactured by Advanced Surgical Concepts (ASC) Ltd. of Bray, Ireland. Olympus America Inc. is the exclusive U.S. distributor of the system, which is indicated to contain and isolate tissue during, or prior to, surgical removal and/or extracorporeal manual morcellation.

Key Points: 
  • Guardenia is the latest innovation in their contained tissue extraction product portfolio for gynecological procedures and is manufactured by Advanced Surgical Concepts (ASC) Ltd. of Bray, Ireland.
  • Olympus America Inc. is the exclusive U.S. distributor of the system, which is indicated to contain and isolate tissue during, or prior to, surgical removal and/or extracorporeal manual morcellation.
  • The Guardenia system is designed to prevent the escape of cells into the abdominal cavity during extracorporeal manual morcellation, and its integrated guard provides protection against inadvertent damage from sharp surgical instruments around the incision.
  • Guardenia maximizes the amount of available space in the incision during a procedure by encroaching less into the incision and maintaining a stable protective area to complete manual tissue morcellation.

Ark Surgical Receives FDA Clearance for the LapBox Tissue Containment Removal System for Manual Morcellation

Retrieved on: 
Tuesday, September 13, 2022
Aurora, CO, Woman, Risk, FDA, Food, Company, American Association, Environment, NGT, CEO, Pain, Today, US Foods, Association, Congress, AAGL, Food and Drug Administration, Morcellator, Medical imaging, Pharmaceutical industry, Medical device

NAZARETH, Israel, Sept. 13, 2022 /PRNewswire/ -- Ark Surgical Ltd., an Israeli medical device company, announced today that it has received US Food and Drug Administration (FDA) clearance for its patented LapBox tissue containment removal system for manual morcellation. Designed to enable the safe and simple removal of tissue, the LapBox empowers gynecologists to use manual morcellation for minimally invasive laparoscopic procedures as an alternative to higher-risk open surgery.

Key Points: 
  • Designed for the safe and simple removal of tissue, the LapBox empowers gynecologists to use manual morcellation during minimally invasive laparoscopic procedures as an alternative to higher-risk open surgery.
  • NAZARETH, Israel, Sept. 13, 2022 /PRNewswire/ -- Ark Surgical Ltd., an Israeli medical device company, announced today that it has received US Food and Drug Administration (FDA) clearance for its patented LapBox tissue containment removal system for manual morcellation.
  • Designed to enable the safe and simple removal of tissue, the LapBox empowers gynecologists to use manual morcellation for minimally invasive laparoscopic procedures as an alternative to higher-risk open surgery.
  • Ark Surgical is a privately held Israeli medical device company commercializing the novel LapBox tissue containment removal system.

Worldwide Myomectomy Industry to 2026 - Rise in Minimally Invasive Procedures is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, June 21, 2021
Surgery, Health, Gynecological surgery, Clinical medicine, Medicine, Gynaecological neoplasia, Uterine fibroid, Uterine myomectomy, Medical specialties, Surgical instruments, Morcellator, Victor Bonney

According to this, myomectomy procedures were classified under surgeries that can be delayed by several months.

Key Points: 
  • According to this, myomectomy procedures were classified under surgeries that can be delayed by several months.
  • These guidelines resulted in surgeons delaying myomectomy procedures which will impact devices used in the myomectomy market.
  • With the rise in patients with uterine fibroids, the demand for myomectomy procedures will also increase.
  • These factors along with high reimbursement rates and government initiatives contribute to North America occupying the largest share within the Myomectomy market.